

Neoadjuvant Tebentafusp for Uveal Melanoma

NCT06414590

Status	RECRUITING
Phase	Phase 2
Sponsor	Thomas Jefferson University
Enrollment	19 participants

Plain Language Summary

This study tests tebentafusp — a targeted immunotherapy drug — given before surgery (as neoadjuvant treatment) for uveal melanoma, a rare type of eye cancer (melanoma of the eye). The drug specifically targets a protein called gp100, which is found on uveal melanoma cells, and requires a specific immune gene (HLA-A*02:01) to work.

****You may be eligible if...****

- You are 18 or older with a primary uveal melanoma (eye melanoma)
- Your tumor is large (T3 or T4 category) and cannot be surgically removed without removing the entire eye
- You have not yet received any treatment for this cancer
- You carry the HLA-A*02:01 immune marker (a genetic test is required)
- You are willing to have tumor biopsies

****You may NOT be eligible if...****

- You do not carry the HLA-A*02:01 genetic marker
- You have already received treatment for uveal melanoma
- Your tumor could be removed with surgery that preserves the eye
- Your expected survival is less than 12 weeks

Talk to your doctor to see if this trial is right for you.

Key Eligibility Criteria

Inclusion (11)

- Male or female patient age e 18 years of age at the time of informed consent.
- Ability to provide and understand written informed consent prior to any study procedures.
- Willingness to undergo tumor biopsies at baseline and post-Tebentafusp treatment.
- Treatment naïve primary uveal melanoma with T3 or T4 category tumor size that are surgically unresectable (other than complete enucleation of eye).
- No surgical indication to completely remove the tumor without enucleation.

... and 6 more (see full listing online)

Exclusion (32)

- Symptomatic uveal melanoma that requires immediate ophthalmological intervention such as enucleation.
- Evidence of metastatic disease.
- Previous treatment with Tebentafusp.
- Patients with any out-of-range laboratory values defined as:
 - Serum creatinine ≥ 1.5 x upper limit of normal (ULN) and/or creatinine clearance (calculated using Cockcroft-Gault Formula, or measured) < 50 mL/minute

... and 27 more (see full listing online)

<https://clinicaltrials.gov/study/NCT06414590>

Locations (2 total)

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Wills Eye Hospital, Philadelphia, Pennsylvania, United States

<https://clinicaltrials.gov/study/NCT06414590>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by ClinicalTrialsFinder.org.